London Gynaecology Limited 07460151 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of specialists in gynaecology services. Digita Accounts Production Advanced 6.30.9574.0 true 07460151 2024-04-01 2025-03-31 07460151 2025-03-31 07460151 bus:OrdinaryShareClass1 2025-03-31 07460151 bus:Consolidated 2025-03-31 07460151 core:HirePurchaseContracts core:CurrentFinancialInstruments 2025-03-31 07460151 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2025-03-31 07460151 core:CurrentFinancialInstruments 2025-03-31 07460151 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 07460151 core:Non-currentFinancialInstruments 2025-03-31 07460151 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 07460151 core:Goodwill 2025-03-31 07460151 core:BetweenTwoFiveYears 2025-03-31 07460151 core:MoreThanFiveYears 2025-03-31 07460151 core:WithinOneYear 2025-03-31 07460151 core:FurnitureFittingsToolsEquipment 2025-03-31 07460151 core:MotorVehicles 2025-03-31 07460151 bus:SmallEntities 2024-04-01 2025-03-31 07460151 bus:Audited 2024-04-01 2025-03-31 07460151 bus:FilletedAccounts 2024-04-01 2025-03-31 07460151 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 07460151 bus:RegisteredOffice 2024-04-01 2025-03-31 07460151 bus:Director1 2024-04-01 2025-03-31 07460151 bus:Director4 2024-04-01 2025-03-31 07460151 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 07460151 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 07460151 bus:Agent1 2024-04-01 2025-03-31 07460151 core:Goodwill 2024-04-01 2025-03-31 07460151 core:ComputerEquipment 2024-04-01 2025-03-31 07460151 core:FurnitureFittings 2024-04-01 2025-03-31 07460151 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 07460151 core:MotorVehicles 2024-04-01 2025-03-31 07460151 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-04-01 2025-03-31 07460151 core:OtherRelatedParties 2024-04-01 2025-03-31 07460151 countries:EnglandWales 2024-04-01 2025-03-31 07460151 2024-03-31 07460151 core:Goodwill 2024-03-31 07460151 core:FurnitureFittingsToolsEquipment 2024-03-31 07460151 core:MotorVehicles 2024-03-31 07460151 2023-04-01 2024-03-31 07460151 2024-03-31 07460151 bus:OrdinaryShareClass1 2024-03-31 07460151 core:HirePurchaseContracts core:CurrentFinancialInstruments 2024-03-31 07460151 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2024-03-31 07460151 core:CurrentFinancialInstruments 2024-03-31 07460151 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 07460151 core:Non-currentFinancialInstruments 2024-03-31 07460151 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 07460151 core:Goodwill 2024-03-31 07460151 core:BetweenTwoFiveYears 2024-03-31 07460151 core:MoreThanFiveYears 2024-03-31 07460151 core:WithinOneYear 2024-03-31 07460151 core:FurnitureFittingsToolsEquipment 2024-03-31 07460151 core:MotorVehicles 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07460151

Prepared for the registrar

London Gynaecology Limited

Annual Report and Financial Statements

for the Year Ended 31 March 2025

 

London Gynaecology Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 10

 

London Gynaecology Limited

Company Information

Directors

G Bamber

T Gates

Registered office

145 Harley Street
London
W1G 6BJ

Auditors

Hazlewoods LLP Windsor House
Bayshill Road
Cheltenham
GL50 3AT

 

London Gynaecology Limited

(Registration number: 07460151)
Balance Sheet as at 31 March 2025

Note

2025
£

(Unaudited) (As restated)
2024
£

Fixed assets

 

Intangible assets

4

177,500

182,167

Tangible assets

5

591,124

412,748

 

768,624

594,915

Current assets

 

Debtors

6

1,583,948

2,066,250

Cash at bank and in hand

 

2,576,587

1,413,037

 

4,160,535

3,479,287

Creditors: Amounts falling due within one year

7

(1,539,152)

(1,155,033)

Net current assets

 

2,621,383

2,324,254

Total assets less current liabilities

 

3,390,007

2,919,169

Creditors: Amounts falling due after more than one year

7

(60,024)

(50,881)

Deferred tax liabilities

(105,746)

-

Net assets

 

3,224,237

2,868,288

Capital and reserves

 

Called up share capital

9

200

200

Retained earnings

3,224,037

2,868,088

Shareholders' funds

 

3,224,237

2,868,288


These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 16 December 2025 and signed on its behalf by:
 


T Gates
Director

 

London Gynaecology Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
145 Harley Street
London
W1G 6BJ

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Name of parent of group

These financial statements are consolidated in the financial statements of London Gynaecology Group Limited.

The financial statements of London Gynaecology Group Limited may be obtained from Companies House.

Revenue recognition

Turnover is recognised at the fair value of the consideration received or receivable for goods and services
provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair
value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue for the provision of medical services is recognised on the date of the appointment or procedure as this is when the right to the revenue has crystallised. Deposits taken in advance of procedures are held on the balance sheet and released on the date of procedures.

The Company has arrangements whereby it needs to determine if it acts as a principal or an agent as more than one party is involved in providing the goods and services to the customer. The Company acts as a principal if it controls a promised good or service before transferring that good or service to the customer. The Company is an agent if its role is to arrange for another entity to provide the goods or services. Factors considered in making this assessment are most notably the discretion the Company has in establishing the price for the specified good or service and whether the Company is primarily responsible for fulfilling the promise to deliver the service or good. This assessment of control requires judgement in particular in relation to certain service contracts. An example, is the provision of health care services as part of a procedure in an operating theatre where the Company may be assessed to be agent or principal dependent upon the facts and circumstances of the arrangement and the nature of the services being delivered. Where the Company is acting as a principal, revenue is recorded on a gross basis. Where the Company is acting as an agent revenue is recorded at a net amount reflecting the margin earned. In the opinion of the directors, due to the ability to control the price of the procedure and the credit risk taken on, the Company is acting as principal for these transactions.

 

London Gynaecology Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Prior period errors

Revenue for financial year ended 31 March 2024 decreased by £58,508 from £6,177,871 to £6,119,363. Trade debtors decreased by £58,508 from £508,685 to £450,177 due to a restatement of amounts owing from insurance related debtors.

The company has registered for VAT and restated the liability for the year ended 31 March 2024 to £166,472 in respect of retrospective registration. The impact to the profit or loss in the prior year was £58,207.

The directors have restated accruals in the comparative period to include £101,111 of in respect of a rent-free period which has also increased administrative expenses. Brought forward reserves have been reduced by £101,111.

Judgements and estimation uncertainty

These financial statements do not contain any significant judgements or estimation uncertainty.

Going concern
After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Tax

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as
reported in the profit and loss account because it excludes items of income or expense that are taxable or
deductible in other years and it further excludes items that are never taxable or deductible. The company’s
liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the
reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are
recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax
liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference
arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects
neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

London Gynaecology Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures and fittings

20% Straight Line

Computer Equipment

25% Reducing Balance

Motor Vehicles

25% Reducing Balance

Goodwill

Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 5 years.

Intangible assets

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of
net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less
accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful
life and is amortised on a systematic basis over its expected life, which is 5 years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to
benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for
impairment at least annually, or more frequently when there is an indication that the unit may be impaired.
If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the
impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and
then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

straight line over 5 years

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Trade debtors

Trade debtors are amounts due from customers for services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

 

London Gynaecology Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and
rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of
inception and the present value of the minimum lease payments. The related liability is included in the
balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest
elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the
remaining balance of the liability

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.


Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.


Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

 

London Gynaecology Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

Financial instruments (continued)

Impairment (continued)
Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

 

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was as follows:

 

London Gynaecology Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

5

Tangible assets

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost

At 1 April 2024

703,093

224,598

927,691

Additions

328,743

-

328,743

At 31 March 2025

1,031,836

224,598

1,256,434

Depreciation

At 1 April 2024

421,510

93,433

514,943

Charge for the year

117,576

32,791

150,367

At 31 March 2025

539,086

126,224

665,310

Carrying amount

At 31 March 2025

492,750

98,374

591,124

At 31 March 2024

412,748

-

412,748

Hire purchase agreements
Included within the net book value is £75,501 (2024 - £47,283) relating to assets held under hire purchase agreements. The depreciation charge to the financial statements in the year in respect of such assets amounted to £17,739 (2024 - £9,547).

 

6

Debtors

2025
£

(Unaudited) (As restated)
2024
£

Trade debtors

572,122

450,177

Amounts due from group undertakings

330,650

-

Prepayments

215,598

-

Other debtors

465,578

1,616,073

1,583,948

2,066,250

 

London Gynaecology Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

7

Creditors

Note

2025
£

(As restated) (Unaudited)
2024
£

Due within one year

 

Loans and borrowings

8

88,746

69,737

Trade creditors

 

455,490

248,061

Taxation and social security

 

398,151

618,867

Accruals and deferred income

 

500,753

101,111

Other creditors

 

96,012

117,257

 

1,539,152

1,155,033

Note

2025
£

(Unaudited)
2024
£

Due after one year

 

Loans and borrowings

8

60,024

50,881

 

8

Loans and borrowings

Current loans and borrowings

2025
£

(Unaudited)
2024
£

Bank borrowings

-

60,000

Hire purchase contracts

19,935

9,737

Other borrowings

68,811

-

88,746

69,737

Non-current loans and borrowings

2025
£

(Unaudited)
2024
£

Bank borrowings

-

10,000

Hire purchase contracts

60,024

40,881

60,024

50,881

The bank loans were fully repaid during the year.

 

London Gynaecology Limited

Notes to the Financial Statements for the Year Ended 31 March 2025

 

9

Share capital

Allotted, called up and fully paid shares

 

2025

(Unaudited)
2024

 

No.

£

No.

£

Ordinary Shares of £1 each

200

200

200

200

         
 

10

Obligations under leases and hire purchase contracts

Operating leases

The total of future minimum lease payments is as follows:

2025
£

(Unaudited)
2024
£

Not later than one year

300,374

95,029

Later than one year and not later than five years

1,058,477

327,552

Later than five years

264,839

-

1,623,690

422,581

The amount of non-cancellable operating lease payments recognised as an expense during the year was £367,990 (2024 - £287,575).

 

11

Related party transactions

Summary of transactions with key management

Key management personnel are considered to be the directors of the company and key management personnel compensation is disclosed in note 4 to the financial statements.

Summary of transactions with other related parties

During the year ended 31 March 2025, the company paid monitoring fees to the ultimate controlling party of £3,295.

 

12

Parent and ultimate parent undertaking

The company's immediate parent is London Gynaecology Services Limited, incorporated in England and Wales.

 The ultimate parent is London Gynaecology Group Limited, incorporated in England and Wales.

 The directors consider there to be no ultimate controlling party.

 

13

Audit report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 16 December 2025 was James Morter, who signed for and on behalf of Hazlewoods LLP.